KRAS mutation G12D-targeted ONCOlogues (Oncogenuity)

N/A

Report date: 2025/03/20 16:07:28
NME

Base Information

Drug NameKRAS mutation G12D-targeted ONCOlogues (Oncogenuity)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsPancreatic NeoplasmsColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncogenuity Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncogenuity IncColumbia University
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A